Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00588393 · ClinicalTrials.gov registry record · Phase 2

FolateScan in Autoimmune Disease

A Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT00588393: Completed Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis, sponsored by Mayo Clinic.

NCT00588393 is a Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis that has completed, run by Mayo Clinic. The registered enrollment target is 75 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00588393, a Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's disease as well as in healthy persons without these conditions.

Interventions

  • DRUG FolateScan (Technetium Tc 99mEC20)

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2006-09
Est. Completion 2007-12
Phase Phase 2
Mayo Clinic

2,844 total trials

What the finished NCT00588393 record still lists

NCT00588393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower).

The record links to 5 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which FolateScan (Technetium Tc 99mEC20) is the first listed.

NCT00588393 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00588393 about?

NCT00588393 is a clinical study titled "FolateScan in Autoimmune Disease". This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's d...

What is the current status of trial NCT00588393?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-09. Estimated completion is 2007-12.

What conditions does trial NCT00588393 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Crohn's Disease, Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT00588393?

The interventions under investigation include: FolateScan (Technetium Tc 99mEC20) (DRUG).

Who is sponsoring clinical trial NCT00588393?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00588393 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00588393's enrollment target sits among peer trials

75 147th of 315 higher than 167 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00588393, the US trial registry maintained by the National Library of Medicine. NCT00588393 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.